Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 22 May 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Poor survival after liver retransplantation

Survival after liver retransplantation is inferior to that for primary transplantation, but appears to have improved in recent years, find doctors in the September issue of Liver Transplantation.

News image

fiogf49gjkf04

The prevalence of hepatitis C virus (HCV) infection in repeated orthotopic liver transplantation (re-OLT) is increasing. Patient survival may be worse.

In this study, doctors from the United States assessed the prevalence of HCV in re-OLT. They also compared survival between primary OLT and re-OLT for HCV versus non-HCV diseases, and evaluated Model for End-Stage Liver Disease (MELD) scores in re-OLT.

The team analyzed data from the United Network for Organ Sharing database. Patients with malignancy or those who underwent re-OLT within 30 days of primary OLT were excluded.

During the study period a total of 22,120 primary OLTs and 2129 re-OLTs were performed.
Survival after retransplantation was no different for patients with HCV.
Liver Transplantation

The team found that HCV occurred in 43% of primary OLTs and 42% re-OLTs.

They determined that the overall 1-, 3-, and 5-year patient survival rates were 86%, 79%, and 73%, respectively, for primary OLT. However, these rates fell to 67%, 56%, and 52% for re-OLT.

They also determined that the survival rates of patients with HCV at 1, 3, and 5 years were 86%, 76%, and 68%, respectively, for primary OLT. These rates dropped for re-OLT to 61%, 50%, and 45%.

The researchers confirmed that re- OLT survival for patients with HCV was less than for those with autoimmune hepatitis and hepatitis B.

However, survival after re-OLT was no different for those with HCV than for those with all other causes.

The team also found that MELD scores between 11 and 20 were the most common for re-OLT.

A marked decreased in survival was noted in all patients who underwent re-OLT with MELD scores greater than 25.

Dr Kymberly Watt's team concluded, "HCV prevalence in OLT has reached a plateau in recent years".

"Survival after re-OLT is inferior to that for primary OLT, but re-OLT survival appears to have improved".

"Survival after re-OLT is lower in patients with HCV compared with those with autoimmune hepatitis and hepatitis B, but no different than for those with most other liver diseases".

"Survival appeared worse in patients who underwent re-OLT with a MELD score greater than 25".

Liver Transpl 2003; 9: 1019-24
07 October 2003

Go to top of page Email this page Email this page to a colleague

 22 May 2018 
Worldwide H.pylori prevalence
 22 May 2018 
PPI and risk of stroke
 22 May 2018 
Online tool predicts bowel dysfunction severity prior to anterior resection
 21 May 2018 
Fecal incontinence and quality of life in IBD
 21 May 2018 
PPI use and cognitive decline
 21 May 2018 
Depressive symptoms in IBD youth
 18 May 2018 
Esophageal dilatation in clinical practice 
 17 May 2018 
IBD and later extraintestinal manifestations
 17 May 2018 
Repeat stool DNA testing
 17 May 2018 
IBS and chronic fatigue following GI infection
 16 May 2018 
Factors associated with fecal incontinence
 16 May 2018 
Diagnostic delay in Crohn's disease
 16 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 15 May 2018 
Guidelines for management of Crohn's
 15 May 2018 
New therapies for CDI
 15 May 2018 
Hep B in the Grey Zone
 14 May 2018 
Blood test for the diagnosis of fibrotic NASH
 14 May 2018 
Outcomes at bariatric centers of excellence
 14 May 2018 
Management of perianal fistulas in Crohn’s
 11 May 2018 
Detection of undiagnosed celiac disease
 11 May 2018 
Alcohol consumption and drug-induced liver injury
 10 May 2018 
Post‐operative complications in elderly IBD
 10 May 2018 
Colorectal cancer screening
 10 May 2018 
Fibrosis in patients with chronic hepatitis B
 09 May 2018 
Fecal incontinence
 09 May 2018 
Health problems and IBS
 09 May 2018 
Esophageal dilatation in clinical practice 
 07 May 2018 
Omitting antibiotics in uncomplicated acute diverticulitis
 07 May 2018 
Health problems and IBS
 07 May 2018 
Assessment of diminutive colorectal polyps
 04 May 2018 
Factors associated with fecal incontinence
 04 May 2018 
National Institutes of Health workshop and obesity
 04 May 2018 
Colorectal cancer screening and ethnic inequities
 03 May 2018 
Gastrointestinal ultrasound in IBD
 03 May 2018 
Ultransonography in postsurgical recurrence in Crohn's
 02 May 2018 
Symptom assessment in cirrhotic ascites
 02 May 2018 
Hep C antiviral treatment and liver cancer risk
 02 May 2018 
Chronic Hep B
 01 May 2018 
European guidelines on pancreatic cystic neoplasms
 01 May 2018 
Interferon‐free regimens in Hep C
 01 May 2018 
Age at IBD onset and extraintestinal complications
 30 April 2018 
Formula for preterm infants
 30 April 2018 
Primary antibiotic resistance and sequential therapy for H. pylori
 30 April 2018 
Patient-reported outcome measures in IBD trials
 27 April 2018 
Anxiety scale for chronic esophageal disease
 27 April 2018 
Disease activity in eosinophilic esophagitis
 27 April 2018 
Eastern and western practices for endoscopic resection of colorectal lesions
 26 April 2018 
Obesity and physical activity in diverticulosis
 26 April 2018 
Primary sclerosing cholangitis in the USA
 25 April 2018 
Aspirin and pancreatic cancer
 25 April 2018 
Central mediators of irinotecan-induced steatohepatitis
 25 April 2018 
Neuroimaging in Hep C
 24 April 2018 
Scoring system identifies cancer risk in Barrett's
 24 April 2018 
Microbiome in athletes vs sedentary subjects
 23 April 2018 
Genome-wide study on HBV-related acute-on-chronic liver failure
 23 April 2018 
Antibody suitable for further clinical development to complement existing therapeutic strategies for HCV
 23 April 2018 
Sleep deprivation and NAFLD in the USA
 20 April 2018 
Two annexin A11 epitopes targeted by IgG1 and IgG4 autoantibodies were shared between patients with IAC/AIP and IgG4 antibodies blocked binding of IgG1 antibodies to the shared annexin A11 epitopes
 20 April 2018 
Adalimumab with azathioprine in Crohn's
 19 April 2018 
c-Myc expression and pancreatic cancer

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us